Medroxyprogesterone at High Altitude. The Effects on Blood Gases, Cerebral Regional Oxygenation, and Acute Mountain Sickness

Wilderness and Environmental Medicine

Volumn 15, Issue 1, 2004, Pages 25-31

  Wright, Alex D ^a   Beazley, Margaret F ^a   Bradwell, Arthur R ^a,b   Chesner, Ian M ^a   Clayton, Richard N ^a   Forster, Peter J G ^a   Hillenbrand, Peter ^a   Imray, Christopher H E ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Binding Site Group Ltd   (United Kingdom)

Author keywords

Acetazolamide; Acute mountain sickness; High altitude; Oxygenation; Progesterone

Indexed keywords

ACETAZOLAMIDE; ADENOSINE TRIPHOSPHATASE; ALMITRINE; ASCORBIC ACID; DEXAMETHASONE; MEDROXYPROGESTERONE; NIFEDIPINE; PLACEBO; PROGESTERONE; RESPIRATORY STIMULANT AGENT;

ADULT; ALTITUDE; ALTITUDE ACCLIMATIZATION; ALTITUDE DISEASE; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD GAS ANALYSIS; BLOOD SAMPLING; BRAIN OXYGEN CONSUMPTION; BRAIN REGION; CAPILLARY BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UTILIZATION; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERVENTILATION; LIBIDO DISORDER; MALE; NORMAL HUMAN; OXYGEN SATURATION; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PILOT STUDY; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOM; TISSUE OXYGENATION; VAGINA BLEEDING;

EID: 1542313969     PISSN: 10806032     EISSN: None     Source Type: Journal    
DOI: 10.1580/1080-6032(2004)015[0025:MAHATE]2.0.CO;2     Document Type: Article

References (25)

1. Shlim DR, Houston R. Helicopter rescues and deaths among trekkers in Nepal. JAMA. 1989;261:1017-1019.
2. BMRES Mountain Sickness Study Group. Acetazolamide in the control of acute mountain sickness. Lancet. 1981;i: 180-183.
3. Wright AD, Winterborn MH, Forster PJ, et al. Carbonic anhydrase inhibition in the immediate therapy of acute mountain sickness. J Wilderness Med. 1994;5:49-55.
4. Bärtsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O. Prevention of high-altitude pulmonary oedema by nifedipine. N Engl J Med. 1991;325:1284-1289.
5. Hackett P, Roach R, Wood R, et al. Dexamethasone for prevention and treatment for acute mountain sickness. Aviat Space Environ Med. 1988;59:950-954.
6. Bradwell AR, Imray CHE, Wright AD, Delamere J, and the BMRES. Acetazolamide or nifedipine in acute mountain sickness prophylaxis. In: Sutton JR, Houston CS, Coates G, eds. Hypoxia and Molecular Medicine. Burlington, VT: Queen City Printers Inc; 1993:294.
7. Hohenhaus E, Niroomand F, Goerre S, Vock P, Oelz O, Bärtsch P. Nifedipine does not prevent acute mountain sickness. Am J Respir Crit Care Med. 1994;150:857-860.
8. Johnson TS, Rock PB, Fulco CS, et al. Prevention of acute mountain sickness by dexamethasone. N Engl J Med. 1984;310:683-686.
9. Moore LG, Harrison GL, McCullough RE, et al. Low acute hypoxic ventilatory response and hypoxic depression in acute altitude sickness. J Appl Physiol. 1986;40:1407-1412.
10. Hackett PH, Roach RC, Harrison GL, Schoene RB, Mills WJ. Respiratory stimulants and sleep periodic breathing at high altitude. Almitrine versus acetazolamide. Am Rev Respir Dis. 1987;135:896-898.
11. Kryger M, McCullough RE, Collins D, et al. Treatment of excessive polycythemia of high altitude with respiratory stimulant drugs. Am Rev Respir Dis. 1978;117:455-464.
12. Milerad J, Lagercrantz H, Lofgren O. Alveolar hypoventilation treated with medroxyprogesterone. Arch Dis Childhood. 1985;60:150-155.
13. Roof RL, Duvdevani R, Stein DG. Progesterone treatment attenuates brain oedema following contusion injury in male and female rats. Restorative Neurol Neurosci. 1992;4:425-427.
14. Roach RC, Bärtsch P, Oelz O, Hackett PH, and the Lake Louise AMS Scoring Consensus Committee. The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Hanston CS, Coates G, eds. Hypoxia and Molecular Medicine. Burlington, VT: Queen City Press; 1993:272-274.
15. Imray CHE, Barnett NJ, Walsh S, et al. Near-infrared spectroscopy in the assessment of cerebral oxygenation at high altitude. Wilderness Environ Med. 1998;9:198-203.
16. Cohen L, Holliday M. Statisticsfor Social Scientists. London: Harper & Row; 1982.
17. Harvey T. Om Mani Padme Hum. Lancet. 1993;342:363.
18. Wright AD, Forster PJG, Cadigan P, Fletcher RF, Bradwell AR, and BMRES. Refinements of the Lake Louise self-reporting AMS questionnaire. In: Sutton JR, Houston CS, Coates G, eds. Hypoxia and the Brain. Burlington, VT: Queen City Press; 1995:No. 57:21.
19. Bayliss DA, Millhorn DE. Central neural mechanisms of progesterone action: application to the respiratory system. J Appl Physiol. 1992;73:393-404.
20. Hannhart B, Pickett C, Grindlay Moore L. Effects of oestrogen and progesterone on carotid body neural output responsiveness to hypoxia. J Appl Physiol. 1990;68:1909-1916.
21. Hellman L, Yoshida K, Zumoff B, Levin J, Kream J, Fukishima D. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab. 1976;42:912-917.
22. Johnson TS, Rock PB. Acute mountain sickness. N Engl J Med. 1988;319:841-845.
23. Harris CW, Shields JL, Hannon JP. Acute altitude sickness in females. Aerospace Med. 1966;37:1163-1167.
24. Hackett PH, Rennie D. The incidence, importance and prophylaxis of acute mountain sickness. Lancet. 1976;2:1149-1155.
25. Honigman B, Theis MK, Koziol-McLain J, et al. Acute mountain sickness in a general tourist population at moderate altitudes. Ann Intern Med. 1993;118:587-591.